Phase I/II study of irinotecan, 5-fluorouracil, and I-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer

International Journal of Clinical Oncology

Volumn 9, Issue 5, 2004, Pages 364-368

  Goto, Ayumu ^a   Yamada, Yasuhide ^a   Hosokawa, Ayumu ^a   Ura, Takashi ^a   Arai, Tatsuhiro ^a   Hamaguchi, Tetsuya ^a   Muro, Kei ^a   Shimada, Yasuhiro ^a   Shirao, Kuniaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

5 Fluorouracil; Colorectal cancer; Irinotecan; l Leucovorin; Phase I II study

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPONATREMIA; JAPAN; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 10944252903     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-004-0407-3     Document Type: Article

References (14)

1. The Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896-903
2. Cunningham D, Pyrhonen S, James RD, et al. (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418
3. Rougier P, Van Cutsem E, Bajetta E, et al. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412
4. Saltz LB, Cox JV, Blanke C, et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914
5. Douillard JY, Cunningham D, Roth AD, et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047
6. Rothenberg ML, Meropol NJ, Poplin EA, et al. (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801-3807
7. Erlichman C, Goldberg RM, O'Connell MJ, et al. (2001) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 344:305-307
8. Elfring G, Emanuel D, Rastogi R, et al. (2002) Pattern of use and mortality in the community oncology practice setting among patients receiving first-line weekly bolus irinotecan/ 5-fluorouracil/leucovorin for metastatic colorectal cancer. Proc ASCO 21:530
9. Knight RD, Miller L, Elfring G, et al. (2001) Evaluation of age, gender, performance status (PS), and organ dysfunction as predictors of toxicity with first-line irinotecan, fluorouracil, leucovorin therapy of metastatic colorectal cancer (abstract). Proc ASCO 20:535
10. The Japan Clinical Oncology Study Group (1999) National Cancer Institute common toxicity criteria. Jpn J Cancer Chemother 26:1084-1144
11. Therasse P, Arbuck SG, Eisenheuer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
12. Van Groeningen CJ, Van der Vijgh WJF, Baars JJ, et al. (2000) Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines. Clin Cancer Res 6:1342-1346
13. Venook AP, Enders Klein C, Fleming G, et al. (2003) A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 14:1783-1790
14. Wasserman E, Myara A, Lokiec F, et al. (1997) Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 8:1049-1051